• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022

    8/3/22 10:38:04 AM ET
    $AAWW
    $AINV
    $ATHE
    $CAT
    Transportation Services
    Consumer Discretionary
    Finance/Investors Services
    Finance
    Get the next $AAWW alert in real time by email

     

    Upgrades

    • Bernstein upgraded the previous rating for Cognex Corp (NASDAQ:CGNX) from Market Perform to Outperform. In the second quarter, Cognex showed an EPS of $0.41, compared to $0.43 from the year-ago quarter. The stock has a 52-week-high of $80.30 and a 52-week-low of $41.69. At the end of the last trading period, Cognex closed at $49.72.
    • According to RBC Capital, the prior rating for Sealed Air Corp (NYSE:SEE) was changed from Sector Perform to Outperform. In the second quarter, Sealed Air showed an EPS of $1.01, compared to $0.79 from the year-ago quarter. The stock has a 52-week-high of $70.72 and a 52-week-low of $55.08. At the end of the last trading period, Sealed Air closed at $56.17.
    • RBC Capital upgraded the previous rating for Clearwater Paper Corp (NYSE:CLW) from Sector Perform to Outperform. In the second quarter, Clearwater Paper showed an EPS of $1.11, compared to $1.07 from the year-ago quarter. At the moment, the stock has a 52-week-high of $38.88 and a 52-week-low of $25.07. Clearwater Paper closed at $34.80 at the end of the last trading period.
    • Citigroup upgraded the previous rating for The Mosaic Co (NYSE:MOS) from Neutral to Buy. Mosaic earned $3.64 in the second quarter, compared to $1.17 in the year-ago quarter. The stock has a 52-week-high of $79.28 and a 52-week-low of $37.08. At the end of the last trading period, Mosaic closed at $52.22.
    • Raymond James upgraded the previous rating for Uber Technologies Inc (NYSE:UBER) from Market Perform to Outperform. For the second quarter, Uber Technologies had an EPS of $0.47, compared to year-ago quarter EPS of $0.38. The current stock performance of Uber Technologies shows a 52-week-high of $45.90 and a 52-week-low of $19.89. Moreover, at the end of the last trading period, the closing price was at $29.25.
    • For Xylem Inc (NYSE:XYL), Credit Suisse upgraded the previous rating of Underperform to Neutral. Xylem earned $0.66 in the second quarter, compared to $0.66 in the year-ago quarter. The current stock performance of Xylem shows a 52-week-high of $121.05 and a 52-week-low of $72.08. Moreover, at the end of the last trading period, the closing price was at $95.37.
    • For CF Industries Holdings Inc (NYSE:CF), Citigroup upgraded the previous rating of Neutral to Buy. For the second quarter, CF Industries Holdings had an EPS of $6.19, compared to year-ago quarter EPS of $1.14. The current stock performance of CF Industries Holdings shows a 52-week-high of $113.48 and a 52-week-low of $63.10. Moreover, at the end of the last trading period, the closing price was at $98.17.
    • For Atlas Air Worldwide Holdings Inc (NASDAQ:AAWW), Wolfe Research upgraded the previous rating of Underperform to Peer Perform. In the first quarter, Atlas Air Worldwide Hldgs showed an EPS of $2.99, compared to $2.45 from the year-ago quarter. The current stock performance of Atlas Air Worldwide Hldgs shows a 52-week-high of $97.13 and a 52-week-low of $58.70. Moreover, at the end of the last trading period, the closing price was at $87.37.

    See all analyst ratings upgrades.

     

    Downgrades

    • According to B. Riley Securities, the prior rating for Sierra Wireless Inc (NASDAQ:SWIR) was changed from Buy to Neutral. In the first quarter, Sierra Wireless showed an EPS of $0.23, compared to $0.26 from the year-ago quarter. The current stock performance of Sierra Wireless shows a 52-week-high of $30.69 and a 52-week-low of $13.44. Moreover, at the end of the last trading period, the closing price was at $28.15.
    • Macquarie downgraded the previous rating for XPeng Inc (NYSE:XPEV) from Outperform to Neutral. XPeng earned $0.28 in the first quarter, compared to $0.13 in the year-ago quarter. The stock has a 52-week-high of $51.50 and a 52-week-low of $18.01. At the end of the last trading period, XPeng closed at $24.15.
    • William Blair downgraded the previous rating for Sierra Wireless Inc (NASDAQ:SWIR) from Outperform to Market Perform. In the first quarter, Sierra Wireless showed an EPS of $0.23, compared to $0.26 from the year-ago quarter. The stock has a 52-week-high of $30.69 and a 52-week-low of $13.44. At the end of the last trading period, Sierra Wireless closed at $28.15.
    • According to Needham, the prior rating for Semtech Corp (NASDAQ:SMTC) was changed from Buy to Hold. Semtech earned $0.80 in the first quarter, compared to $0.53 in the year-ago quarter. At the moment, the stock has a 52-week-high of $92.14 and a 52-week-low of $49.91. Semtech closed at $55.34 at the end of the last trading period.
    • According to Guggenheim, the prior rating for Incyte Corp (NASDAQ:INCY) was changed from Buy to Neutral. Incyte earned $1.01 in the second quarter, compared to $0.80 in the year-ago quarter. At the moment, the stock has a 52-week-high of $84.86 and a 52-week-low of $65.07. Incyte closed at $72.58 at the end of the last trading period.
    • For Caterpillar Inc (NYSE:CAT), Bernstein downgraded the previous rating of Outperform to Market Perform. In the second quarter, Caterpillar showed an EPS of $3.18, compared to $2.60 from the year-ago quarter. At the moment, the stock has a 52-week-high of $237.90 and a 52-week-low of $167.08. Caterpillar closed at $183.51 at the end of the last trading period.
    • According to Stephens & Co., the prior rating for Cognex Corp (NASDAQ:CGNX) was changed from Overweight to Equal-Weight. In the second quarter, Cognex showed an EPS of $0.41, compared to $0.43 from the year-ago quarter. The stock has a 52-week-high of $80.30 and a 52-week-low of $41.69. At the end of the last trading period, Cognex closed at $49.72.
    • Canaccord Genuity downgraded the previous rating for Sierra Wireless Inc (NASDAQ:SWIR) from Buy to Hold. In the first quarter, Sierra Wireless showed an EPS of $0.23, compared to $0.26 from the year-ago quarter. The current stock performance of Sierra Wireless shows a 52-week-high of $30.69 and a 52-week-low of $13.44. Moreover, at the end of the last trading period, the closing price was at $28.15.
    • According to JP Morgan, the prior rating for Hydrofarm Holdings Group Inc (NASDAQ:HYFM) was changed from Overweight to Neutral. In the first quarter, Hydrofarm Holdings Group showed an EPS of $0.17, compared to $0.19 from the year-ago quarter. The stock has a 52-week-high of $29.14 and a 52-week-low of $2.96. At the end of the last trading period, Hydrofarm Holdings Group closed at $3.27.
    • According to Credit Suisse, the prior rating for Esperion Therapeutics Inc (NASDAQ:ESPR) was changed from Neutral to Underperform. In the second quarter, Esperion Therapeutics showed an EPS of $1.05, compared to $1.67 from the year-ago quarter. At the moment, the stock has a 52-week-high of $7.13 and a 52-week-low of $3.28. Esperion Therapeutics closed at $5.87 at the end of the last trading period.
    • According to Roth Capital, the prior rating for Knowles Corp (NYSE:KN) was changed from Buy to Neutral. Knowles earned $0.33 in the second quarter, compared to $0.31 in the year-ago quarter. The stock has a 52-week-high of $23.81 and a 52-week-low of $16.59. At the end of the last trading period, Knowles closed at $19.07.

    See all analyst ratings downgrades.

     

    Initiations

    • Argus Research initiated coverage on WR Berkley Corp (NYSE:WRB) with a Buy rating. The price target for WR Berkley is set to $72.00. In the second quarter, WR Berkley showed an EPS of $1.12, compared to $1.17 from the year-ago quarter. The current stock performance of WR Berkley shows a 52-week-high of $99.68 and a 52-week-low of $60.94. Moreover, at the end of the last trading period, the closing price was at $61.11.
    • With a Buy rating, DA Davidson initiated coverage on FiscalNote Holdings Inc (NYSE:NOTE). The price target seems to have been set at $8.50 for FiscalNote Holdings. At the moment, the stock has a 52-week-high of $9.25 and a 52-week-low of $5.55. FiscalNote Holdings closed at $6.93 at the end of the last trading period.
    • With a Buy rating, Jefferies initiated coverage on ImmunityBio Inc (NASDAQ:IBRX). The price target seems to have been set at $8.00 for ImmunityBio. For the first quarter, ImmunityBio had an EPS of $0.26, compared to year-ago quarter EPS of $0.21. The current stock performance of ImmunityBio shows a 52-week-high of $7.85 and a 52-week-low of $2.60. Moreover, at the end of the last trading period, the closing price was at $3.73.
    • Barclays initiated coverage on Reinsurance Group of America Inc (NYSE:RGA) with a Equal-Weight rating. The price target for Reinsurance Group is set to $120.00. For the first quarter, Reinsurance Group had an EPS of $0.47, compared to year-ago quarter EPS of $1.24. At the moment, the stock has a 52-week-high of $127.22 and a 52-week-low of $97.61. Reinsurance Group closed at $113.55 at the end of the last trading period.
    • With a Buy rating, Ladenburg Thalmann initiated coverage on Alterity Therapeutics Ltd (NASDAQ:ATHE). The price target seems to have been set at $2.00 for Alterity Therapeutics. The stock has a 52-week-high of $1.23 and a 52-week-low of $0.56. At the end of the last trading period, Alterity Therapeutics closed at $0.60.
    • With a Buy rating, HC Wainwright & Co. initiated coverage on Valneva SE (NASDAQ:VALN). The price target seems to have been set at $34.00 for Valneva. For the first quarter, Valneva had an EPS of $0.52, compared to year-ago quarter EPS of $0.72. The current stock performance of Valneva shows a 52-week-high of $53.11 and a 52-week-low of $13.71. Moreover, at the end of the last trading period, the closing price was at $19.84.
    • With an Overweight rating, Stephens & Co. initiated coverage on ModivCare Inc (NASDAQ:MODV). The price target seems to have been set at $145.00 for ModivCare. For the first quarter, ModivCare had an EPS of $1.57, compared to year-ago quarter EPS of $1.92. The stock has a 52-week-high of $148.46 and a 52-week-low of $80.55. At the end of the last trading period, ModivCare closed at $101.59.
    • With a Buy rating, Goldman Sachs initiated coverage on Kymera Therapeutics Inc (NASDAQ:KYMR). The price target seems to have been set at $40.00 for Kymera Therapeutics. For the first quarter, Kymera Therapeutics had an EPS of $0.71, compared to year-ago quarter EPS of $0.29. At the moment, the stock has a 52-week-high of $65.44 and a 52-week-low of $13.15. Kymera Therapeutics closed at $22.75 at the end of the last trading period.

    See all analyst ratings initiations.

    Get the next $AAWW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAWW
    $AINV
    $ATHE
    $CAT

    CompanyDatePrice TargetRatingAnalyst
    W.R. Berkley Corporation
    $WRB
    4/23/2026$68.00Underperform → Market Perform
    BMO Capital Markets
    XPeng Inc.
    $XPEV
    4/22/2026Neutral → Underperform
    BNP Paribas Exane
    Valneva SE
    $VALN
    4/22/2026$4.90Neutral → Sell
    Goldman
    Xylem Inc.
    $XYL
    4/21/2026$132.00Buy → Neutral
    UBS
    W.R. Berkley Corporation
    $WRB
    4/9/2026$71.00Overweight → Neutral
    Cantor Fitzgerald
    Mosaic Company
    $MOS
    3/26/2026$27.00Buy → Neutral
    UBS
    W.R. Berkley Corporation
    $WRB
    3/25/2026$73.00Buy → Neutral
    Brean Capital
    XPeng Inc.
    $XPEV
    3/23/2026$19.00Outperform → Neutral
    Macquarie
    More analyst ratings

    $AAWW
    $AINV
    $ATHE
    $CAT
    SEC Filings

    View All

    Knowles Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Knowles Corp (0001587523) (Filer)

    4/23/26 4:05:17 PM ET
    $KN
    Consumer Electronics/Appliances
    Consumer Staples

    SEC Form 6-K filed by XPeng Inc.

    6-K - XPENG INC. (0001810997) (Filer)

    4/23/26 11:29:15 AM ET
    $XPEV
    Auto Manufacturing
    Industrials

    SEC Form 144 filed by Kymera Therapeutics Inc.

    144 - Kymera Therapeutics, Inc. (0001815442) (Subject)

    4/22/26 4:52:28 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAWW
    $AINV
    $ATHE
    $CAT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAWW
    $AINV
    $ATHE
    $CAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Mitsui Sumitomo Insurance Co Ltd bought $18,745,005 worth of shares (258,176 units at $72.61) (SEC Form 4)

    4 - BERKLEY W R CORP (0000011544) (Issuer)

    3/3/26 8:00:13 PM ET
    $WRB
    Property-Casualty Insurers
    Finance

    Large owner Mitsui Sumitomo Insurance Co Ltd bought $21,494,315 worth of shares (300,000 units at $71.65) (SEC Form 4)

    4 - BERKLEY W R CORP (0000011544) (Issuer)

    2/27/26 7:30:41 PM ET
    $WRB
    Property-Casualty Insurers
    Finance

    Large owner Mitsui Sumitomo Insurance Co Ltd bought $39,381,432 worth of shares (553,654 units at $71.13) (SEC Form 4)

    4 - BERKLEY W R CORP (0000011544) (Issuer)

    2/25/26 8:02:15 PM ET
    $WRB
    Property-Casualty Insurers
    Finance

    $AAWW
    $AINV
    $ATHE
    $CAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AAWW
    $AINV
    $ATHE
    $CAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 4 filed by Resnik Josh

    4 - FiscalNote Holdings, Inc. (0001823466) (Issuer)

    4/21/26 9:16:06 PM ET
    $NOTE
    Real Estate

    SEC Form 4 filed by Aman Todd

    4 - FiscalNote Holdings, Inc. (0001823466) (Issuer)

    4/21/26 9:15:06 PM ET
    $NOTE
    Real Estate

    SEC Form 4 filed by Cagnoni Pablo J

    4 - INCYTE CORP (0000879169) (Issuer)

    4/21/26 4:09:07 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    W.R. Berkley upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded W.R. Berkley from Underperform to Market Perform and set a new price target of $68.00

    4/23/26 7:47:02 AM ET
    $WRB
    Property-Casualty Insurers
    Finance

    XPeng downgraded by BNP Paribas Exane

    BNP Paribas Exane downgraded XPeng from Neutral to Underperform

    4/22/26 7:54:22 AM ET
    $XPEV
    Auto Manufacturing
    Industrials

    Valneva SE downgraded by Goldman with a new price target

    Goldman downgraded Valneva SE from Neutral to Sell and set a new price target of $4.90

    4/22/26 7:54:11 AM ET
    $VALN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAWW
    $AINV
    $ATHE
    $CAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    W. R. Berkley Corporation Names R. Christopher DeLauder President of Berkley Environmental

    W. R. Berkley Corporation (NYSE:WRB) today announced the appointment of R. Christopher DeLauder as president of Berkley Environmental. He succeeds Kenneth J. Berger, who has been named chair of the business. The appointments are effective immediately. Mr. DeLauder has nearly 40 years of experience in the insurance industry, focused almost exclusively in the environmental sector. He joined Berkley Environmental as vice president in 2010 and most recently served as executive vice president. Mr. Berger will support the Berkley Environmental team through the transition and remain a key member of W. R. Berkley Corporation management engaged in other initiatives and activities. Commenting on

    4/23/26 4:15:00 PM ET
    $WRB
    Property-Casualty Insurers
    Finance

    Knowles Reports Q1 2026 Financial Results and Provides Outlook for Q2 2026

    Q1 Revenues Increased 16% on a Year over Year Basis to $153 million Q1 Diluted EPS from Continuing Operations increased $0.13 on a Year over Year Basis Q1 Non-GAAP Diluted EPS from Continuing Operations Increased 50% on a Year over Year Basis to $0.27 Knowles Corporation (NYSE:KN), a leading manufacturer of specialty electronic components, including high performance capacitors, radio frequency ("RF") filters, advanced medtech microphones, and balanced armature speakers, today announced results for the quarter ended March 31, 2026. "We started 2026 delivering strong first quarter revenues and non-GAAP diluted EPS which was at or above the high-end of our guided ranges," commented Jef

    4/23/26 4:05:00 PM ET
    $KN
    Consumer Electronics/Appliances
    Consumer Staples

    Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Bioscien

    4/23/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAWW
    $AINV
    $ATHE
    $CAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ModivCare Inc.

    SC 13D/A - ModivCare Inc (0001220754) (Subject)

    12/13/24 9:05:42 PM ET
    $MODV
    Transportation Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by ModivCare Inc.

    SC 13D/A - ModivCare Inc (0001220754) (Subject)

    12/13/24 5:07:48 PM ET
    $MODV
    Transportation Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by ModivCare Inc.

    SC 13D/A - ModivCare Inc (0001220754) (Subject)

    12/9/24 7:46:13 PM ET
    $MODV
    Transportation Services
    Consumer Discretionary

    $AAWW
    $AINV
    $ATHE
    $CAT
    Leadership Updates

    Live Leadership Updates

    View All

    W. R. Berkley Corporation Names R. Christopher DeLauder President of Berkley Environmental

    W. R. Berkley Corporation (NYSE:WRB) today announced the appointment of R. Christopher DeLauder as president of Berkley Environmental. He succeeds Kenneth J. Berger, who has been named chair of the business. The appointments are effective immediately. Mr. DeLauder has nearly 40 years of experience in the insurance industry, focused almost exclusively in the environmental sector. He joined Berkley Environmental as vice president in 2010 and most recently served as executive vice president. Mr. Berger will support the Berkley Environmental team through the transition and remain a key member of W. R. Berkley Corporation management engaged in other initiatives and activities. Commenting on

    4/23/26 4:15:00 PM ET
    $WRB
    Property-Casualty Insurers
    Finance

    Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

    MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Ms Ann Cunningham to its Board of Directors as an independent Non-Executive Director, effective 17th April 2026. Ms Cunningham's appointment further strengthens Alterity's Board composition, adding significant global commercial and strategic expertise as the Company transitions toward late-stage development in Multiple System Atrophy (MSA). Ms Cunningham brings more than 25 years of global pharmac

    4/17/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    W. R. Berkley Corporation Names Christopher T. Reichardt President of Berkley Oil & Gas

    W. R. Berkley Corporation (NYSE:WRB) today announced the appointment of Christopher T. Reichardt as president of Berkley Oil & Gas. He succeeds Linda A. Eppolito, who has been named chair of the business. The appointments are effective immediately. Mr. Reichardt has over 20 years of experience in the oil and gas insurance industry, more than 15 years of which was spent at Berkley Oil & Gas. He most recently served as senior vice president and chief underwriting officer for the business. Commenting on the appointment, W. Robert Berkley, Jr., president and chief executive officer of W. R. Berkley Corporation, said: "Chris has made tremendous contributions to Berkley Oil & Gas during his t

    4/16/26 4:15:00 PM ET
    $WRB
    Property-Casualty Insurers
    Finance

    $AAWW
    $AINV
    $ATHE
    $CAT
    Financials

    Live finance-specific insights

    View All

    Knowles Reports Q1 2026 Financial Results and Provides Outlook for Q2 2026

    Q1 Revenues Increased 16% on a Year over Year Basis to $153 million Q1 Diluted EPS from Continuing Operations increased $0.13 on a Year over Year Basis Q1 Non-GAAP Diluted EPS from Continuing Operations Increased 50% on a Year over Year Basis to $0.27 Knowles Corporation (NYSE:KN), a leading manufacturer of specialty electronic components, including high performance capacitors, radio frequency ("RF") filters, advanced medtech microphones, and balanced armature speakers, today announced results for the quarter ended March 31, 2026. "We started 2026 delivering strong first quarter revenues and non-GAAP diluted EPS which was at or above the high-end of our guided ranges," commented Jef

    4/23/26 4:05:00 PM ET
    $KN
    Consumer Electronics/Appliances
    Consumer Staples

    Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Bioscien

    4/23/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion to Report First Quarter 2026 Financial Results on May 7

    ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. About Esperion Therapeutics Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical c

    4/23/26 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care